Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy
Authors' conclusion
Regarding STDR, fenofibrate benefit is greatest in type 2 diabetes patients with the lowest baseline HP levels, which may reflect patients more susceptible to oxidative retinal injury. All HP phenotypes benefit from fenofibrate.
Study context
- Population
- Australasian adults with T2D in the FIELD trial
- Participants
- 8,047 adults
- Comparison
- Fenofibrate vs placebo, by haptoglobin (HP) phenotype and levels
- Primary endpoint
- New first on-trial sight-threatening diabetic retinopathy (STDR)
- Follow-up
- Five years
Primary result
As reported in the abstract
STDR, fenofibrate vs placebo, by baseline HP level tertile
Fenofibrate vs PlaceboHazard ratio (95% CI)P value
Lowest baseline HP level tertile
0.41(0.26–0.65)
P = 0.019for heterogeneityHP tertile 2
0.82(0.56–1.21)
HP tertile 3
0.84(0.56–1.27)
- Fenofibrate benefit on sight-threatening diabetic retinopathy (STDR) vs placebo overall
- −32 %
Further findings
STDR events · five years
- New first on-trial STDR events
- 307
- Baseline HP levels and phenotype were not related to STDR risk
HP levels during six-week fenofibrate run-in · six weeks
- Fenofibrate reduced HP levels
- 20.7 %
Original publication
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy. Diabetes Res Clin Pract. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →